A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer
Open Access
- 3 June 2010
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 67 (4) , 751-764
Abstract
To characterize the cardiovascular profile of sorafenib, a multitargeted kinase inhibitor, in patients with advanced cancer.Keywords
This publication has 43 references indexed in Scilit:
- Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599Journal of Clinical Oncology, 2010
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation TrialJournal of Clinical Oncology, 2009
- Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysisAnnals of Oncology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer TherapeuticsCirculation, 2008
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007
- Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinomaAnnals of Oncology, 2007
- Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid TumorsThe Oncologist, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Vascular Endothelial Growth Factor Blockade Promotes the Transition From Compensatory Cardiac Hypertrophy to Failure in Response to Pressure OverloadHypertension, 2006